The role of omalizumab in the treatment of adults with severe allergic asthma
Keywords:
severe asthma, omalizumab, allergyAbstract
Backg round: Omalizumab is a recombinant humanized anti-IgE antibody. It has been used in the treatment of severe allergic asthma since 2007 in Slovenija. Our clinical experience with omalizumab-treated severe allergic asthma patients are presented in this manuscript.Me tho ds: Severe asthma patients who have started tretment with omalizumab at our clinic from october 2007 to december 2011 were included in this study. Patients were treated with subcutaneus applications of omalizumab every 2 or 4 weeks, dosed according to body weight and baseline IgE. Outcome measures after one year of treatment were: pulmonary function measured as FEV1, ACT (athma control test) score, number of asthma exacerbations/year, the dose of methylprednisolone needed in regular asthma tretment, and side effects. Results: We included 15 patients with severe allergic asthma in the treatment with omalizumab.Downloads
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
